HOME >> MEDICINE >> NEWS
Farnesyl transferase inhibitor can help patients at high-risk for developing AML

SAN DIEGO - The University of Texas M. D. Anderson Cancer Center offers these news items presented at the annual meeting of the American Society of Hematology (ASH).

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

The drug R115777 (Zarnestra) (tipifarnib) produced responses that ranged from complete responses to improvement in blood counts in about one-third of 82 patients treated at seven different hospitals in the United States, Canada, and Europe, says the study's lead investigator, Razelle Kurzrock, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center.

That level of response, as well as side effects that are well tolerated, can be a boon to the mostly elderly patients who develop the syndrome, Kurzrock says. "It is one more drug that can be tried to help improve blood counts and prevent leukemia development in these patients," she says.

At the time the study began, there was no approved therapy to treat MDS, but recently, the FDA approved use of azacytidine (Vidaza), which is a chemotherapy drug administered subcutaneously. Zarnestra helps about as many patients as Vidaza, "but for diseases like this, you need more than one drug because the syndrome is made up of numerous subtypes," Kurzrock says. "If one drug doesn't help, then the other might; or they could potentially be used together."

Zarnestra belongs to a group of drugs known as farnesyl transferase inhibitors, which block enzymes needed for the activation of cancer-promoting proteins. While the drug was initially believed to act primarily on the ras gene, which is mutated in about 25 percent of MDS patients, recent studies including this one d
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794 1584
University of Texas M. D. Anderson Cancer Center
4-Dec-2004


Page: 1 2

Related medicine news :

1. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
2. COX-2 inhibitors associated with blood pressure elevation
3. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
4. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
5. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk
6. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
7. NIH halts use of COX-2 inhibitor in large cancer prevention trial
8. Breast cancer may be uniquely sensitive to inhibitors of PI3K pathway
9. Aromatase inhibitors should be first-line treatment for certain type of breast cancer
10. Researchers debate recreational use of PDE-5 inhibitors
11. ACE inhibitors not needed for many heart disease patients, according to new study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... ... June 14, 2019 , ... ... Security solutions, today announced it has received the coveted “2019 Best DLP Solution ... that Works Platform along with the latest additions to its Data Security Portfolio ...
(Date:6/14/2019)... , ... June 14, 2019 , ... ... Tempur-Pedic® Mattress & Pink Bag Event® scheduled for Saturday, July 13th. UBCF is ... men and children directly impacted by breast cancer. This second event was added ...
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, a premier ... memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis and supply ... BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana plant to ...
(Date:6/13/2019)... ... June 13, 2019 , ... Pure Ratios, the ... cannabis delivery company, Driven Deliveries, Inc., the only publicly traded cannabis delivery service ... the population of California with overnight cannabis delivery to major thriving markets such ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... everyone in healthcare, today announced that Jon Elwell, the company’s CEO, has been ... DirectTrust is a non-profit health care industry alliance created to support ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... Homecare Homebase ... the new Smart Scheduling product, part of the HCHB Intelligence Suite, at the ... uses complex algorithms to create highly efficient routing, mapping and scheduling for home ...
(Date:6/13/2019)... ... 13, 2019 , ... Access Healthcare , a leading provider of healthcare ... at the HFMA Annual Conference 2019 which will be held on June ... Access Healthcare, says, “HFMA Annual Conference has inspired us in many ways – right ...
(Date:6/13/2019)... ... , ... RxNT announced today that it has been named by ... RxNT is a leader in healthcare technology solutions. This is the fourth time RxNT ... highlight the best software products from North American small businesses. RxNT won the FrontRunner ...
Breaking Medicine Technology:
Cached News: